AL Amyloidosis Research

AL amyloidosis research targets the underlying clonal plasma cell population alongside amyloid fibril clearance, with organ response and survival as competing endpoints.

Our AL Amyloidosis Analysis

• September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

  Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

  PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

• July 10, 2026Journal of Clinical OncologyCARES (CAEL101-301 / CAEL101-302; NCT04504825 & NCT04512235)

  Anselamimab Misses Primary Endpoint Overall but Cuts Mortality 62% in Kappa AL Amyloidosis

  Pooled analysis of the phase III CARES program (CAEL101-301 and CAEL101-302, n=406) testing whether adding the antifibril monoclonal antibody anselamimab to standard anti-plasma cell dyscrasia therapy improves a composite mortality/hospitalization endpoint in advanced (Mayo stage IIIa/IIIb) AL amyloidosis